BioSpace News Archive

Sympazan is an oral soluble film formulation of clobazam, a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older

Recognizing the increased complexity in evidence demands for pharmaceutical products after launch, pharmaceutical companies are boosting their internal Real World Evidence (RWE) capabilities.

Next-Generation Balloon Microcatheters Now Commercially Available in Europe

Technavio analysts forecast the global cell culture consumables market to grow at a CAGR of around 10% during the forecast period, according to their latest market research report.

BioAmber Inc. announces that following a Court order issued on August 28th, 2018, the stay period ordered by the Court in connection with its restructuring process under the terms of the Companies’ Creditors Arrangement Act has been extended until September 18th, 201

Recent Laws in N.Y., Calif., and Ill. Signal Sea Change in Movement HOSPECO® Promoted from Beginning

Technavio analysts forecast the global deep brain stimulation devices market to grow at a CAGR of over 12% during the forecast period, according to their latest market research report.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,020,000 common shares at a price of $0.47 per share to directors of the company.

Mission Health’s Board of Directors announced today that Mission Health and HCA Healthcare (HCA) have entered into a definitive agreement for HCA to acquire Mission Health.

According to data compiled by Global Market Insights, the biotechnology market was valued at USD 330.3 Billion in 2015 and is projected to exceed USD 775.2 Billion while growing at a CAGR of 9.9% from the forecast period between 2016 to 2024.